Krishna Institute of Medical Sciences Limited (KIMS:NSE) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
INR 2,073.67
(+6.20%)
Based on the Krishna Institute of Medical Sciences Limited stock forecast from 3 analysts, the average analyst target price for Krishna Institute of Medical Sciences Limited is INR 2,073.67 over the next 12 months. Krishna Institute of Medical Sciences Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Krishna Institute of Medical Sciences Limited is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Krishna Institute of Medical Sciences Limited’s stock price was INR 1,952.65. Krishna Institute of Medical Sciences Limited’s stock price has changed by -3.33% over the past week, -2.87% over the past month and +30.14% over the last year.
No recent analyst target price found for Krishna Institute of Medical Sciences Limited
No recent average analyst rating found for Krishna Institute of Medical Sciences Limited
Company Overview Krishna Institute of Medical Sciences Limited
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as well as gastroenterology and hepatology, heart and lung transplant, organ transplantation, mother and childcare, and pediatrics services. It also focuses on accident, biochemistry, anesthesiology, bariatric surgery, andrology and infertility, arthroscopy, alzheimers, bone, joint center specialties, and others. The company was incorporated in 1973 and is based in Secunderabad, India. Read Less
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as ...Read More
Frequently Asked Questions About Krishna Institute of Medical Sciences Limited (KIMS:NSE) Stock
Based on ratings from 3 analysts Krishna Institute of Medical Sciences Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on KIMS:NSE's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for KIMS:NSE is INR 2,073.67 over the next 12 months. The maximum analyst target price is INR 2136 while the minimum anlayst target price is INR 1985.
KIMS:NSE stock's Price/Earning ratio is 47.25.
Our analysis grades KIMS:NSE stock's Price / Earning ratio at C-. This means that KIMS:NSE stock's Price/Earning ratio is above 29% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this KIMS:NSE may be undervalued for its sector.
The last closing price of KIMS:NSE's stock was INR 1,952.65.
The most recent market capitalization for KIMS:NSE is INR 160.09B.
Based on targets from 3 analysts, the average taret price for KIMS:NSE is projected at INR 2,073.67 over the next 12 months.
This means that KIMS:NSE's stock price may go up by +6.20% over the next 12 months.
We can't find any ETFs which contains Krishna Institute of Medical Sciences Limited's stock.
As per our most recent records Krishna Institute of Medical Sciences Limited has 4,588 Employees.
Krishna Institute of Medical Sciences Limited's registered address is D. No. 1-8-31/1, Secunderabad, India, 500003.
You can get more information about it from Krishna Institute of Medical Sciences Limited's website at https://www.kimshospitals.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for KIMS:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
